TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02856997
Drug: Chidamide with ICE regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chidamide and ICE regimen, dosage described in arm description
Study: NCT04440345
Drug: IBI362
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT04440345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT04194905
Drug: Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Test Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated Tablets
Study: NCT04194905
Drug: Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Reference Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated Tablets
Study: NCT01483690
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intrathecally to all patients the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35
Study: NCT00090051
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous repeating dose
Study: NCT06346236
Drug: L-thyroxine at a dose of 7.5 µg/kg/d for THOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects diagnosed with THOP (as previously defined) and treated with L-thyroxine at a dose of 7.5 µg/kg/d are less likely to have an impaired ASQ score at 4 years of corrected age.
Study: NCT03449108
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02781519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: small amount of alcohol (quarter teaspoon), with no THC over 10 minutes
Study: NCT01389518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
Study: NCT04338984
Drug: General anesthetic
Normalized name: General anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl is administered at induction - standard dose 5 mcg/kg. Further dosing is based on a multiderivative assessment of nociception (NOL index) and ancillaries such as heart rate and mean arterial blood pressure.
Study: NCT01074021
Drug: placebo plus chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment:4 bottles/w,weekly, 7-8 weeks, one week before radiotherapy~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy: Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)
Study: NCT01041495
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo for cyclobenzaprine ER (AMRIX)
Study: NCT01572675
Drug: etorocoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as 30 mg or 60 mg oral film-coated tablets
Study: NCT01572675
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as 100 mg or 200 mg oral hard capsules
Study: NCT00236925
Drug: Low dose Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 10 mg daily
Study: NCT00236925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04118296
Drug: Anti-Acne Preparations for Topical Use
Normalized name: ANTI-ACNE PREPARATIONS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anti acne cream that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
Study: NCT00038883
Drug: Campath-1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day x 5, starting with the first day of chemotherapy
Study: NCT03961854
Drug: L. johnsonii Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
Study: NCT03961854
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
Study: NCT00214630
Drug: rosuvastatin calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00377975
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01691755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral doses once a day for 26 weeks
Study: NCT00145600
Drug: 2 alternating cycles of VAMP/COP chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.
Study: NCT00145600
Drug: 3 alternating cycles of VAMP/COP chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT
Study: NCT02669238
Drug: Minidril®/Leeloo®
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous per os administration of oestroprogestative treatment. 1 pill a day First line: Minidril® (Levonogestrel 0.15 mg / Ethinylestradiol 0.03 mg) Second line: Leeloo® (Levonogestrel 0.1 mg / Ethinylestradiol 0.02 mg)
Study: NCT03137030
Drug: Norco 5Mg-325Mg Tablet
Normalized name: Norco 5mg-325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
Study: NCT00162721
Drug: doxorubicin, ifosfamide, cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03174041
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose rosuvastatin
Study: NCT03174041
Drug: Rosuvastatin and GDC-0853
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Multiple doses GDC-0853 and single dose rosuvastatin
Study: NCT03174041
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose simvastatin
Study: NCT03174041
Drug: Simvastatin and GDC-0853
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses GDC-0853 and single dose simvastatin
Study: NCT01553032
Drug: Erbitux®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg/m2 initial dose, followed by weekly doses of 250mg/m2 Treatment duration: 7-8 weeks
Study: NCT02030054
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
Study: NCT01266941
Drug: Inhaled FF 200mcg/GW642444M 25mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
Study: NCT01052844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
Study: NCT04565184
Drug: Artemether, Lumefantrine Drug Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child
Study: NCT03924856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle
Study: NCT00368329
Drug: Capecitabine (Xeloda)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO bid daily on RT days: 500mg \& 150mg tabs for dose 825mg/m2 bid AM/PM (total daily dose 1650mg/m2)
Study: NCT02171702
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02160353
Drug: Abiraterone acetate, Prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01670604
Drug: 6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01670604
Drug: Tetraspan, B. Braun, Melsungen, Germany
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00368329
Drug: [18-F] Fluorodeoxyglucose (FDG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-10 mCi IV administration
Study: NCT00272961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet once daily for 12 weeks
Study: NCT00272961
Drug: TBC3711
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tablets once daily for 10 weeks
Study: NCT00272961
Drug: TBC3711
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tablet once daily for 10 weeks
Study: NCT00272961
Drug: TBC3711
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet once daily for 10 weeks
Study: NCT01292785
Drug: Hormones
Normalized name: Other hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: FtM will receive~* 1000mg testosterone undecanoate every 12 weeks (Nebido® 4ml i.m.), or alternatively 50mg testosterone transdermally (Testogel® 5g-bag per day) and~* if menstruation still occurs, additionally either lynestrenol Orgametril® (2-3 tablets/day) or in some cases 0.075mg desogestrel (Cerazette®, 1 tablet/day).~MtF will receive~* 50mg cyproterone acetate daily (Androcur®)~* estradiol 100µg transdermal therapeutic system (TTS) twice a week (Estradot®, Estramon®), especially if subjects age is \> 40 years, or p.o. estradiol 2x2mg (Estrofem®) if subjects age is \< 40 years; alternatively estradiol 0,75-1,5mg (1-2 hubs) transdermally (Estrogel-Gel®) and~* 2,5mg alpha-5-reductase-inhibitor every 2nd day (Finasterid Actavis/ Arcana/ Aurobindo®) in case of extensive hair loss.
Study: NCT03039751
Drug: AdvVEGF-D
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdvVEGF-D will be injected into 10 sites of the myocardium
Study: NCT00272961
Drug: TBC3711
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tablet once daily for 10 weeks
Study: NCT00961766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose IV matched placebo
Study: NCT00559936
Drug: Topical Avastin 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avastin (bevacizumab) 1%
Study: NCT02145988
Drug: DLBS1033
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
Study: NCT02145988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
Study: NCT04115644
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
Study: NCT02212431
Drug: Cysteamine
Normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose will be increased weekly from 450mg od to 450mg bd, to 450mg tds to 450mg qds, will remain on highest dose for 2 weeks
Study: NCT02009007
Drug: dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous infusion during operation
Study: NCT00956956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally Q6 hours for 7 days of dosing.
Study: NCT00969904
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet TID for 12 weeks
Study: NCT03647332
Drug: Steroid Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: steroid injection
Study: NCT02794740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: External Spray
Study: NCT00330798
Drug: nepafenac 0.1%
Normalized name: NEPAFENAC 0.1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
Study: NCT01397864
Drug: rhC1INH or pdC1INH
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
Study: NCT02675231
Drug: Standard of Care Single Agent Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care single-agent chemotherapy of physician's choice administered according to product label
Study: NCT02238977
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressant
Study: NCT00676585
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT00676585
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 100mg
Study: NCT01504867
Drug: Lactose powder
Normalized name: Lactose Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching lactose powder filled capsules will be administered on days 1-7.
Study: NCT00571922
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT02827513
Drug: CTN XR1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03888924
Drug: Bacille Calmette-Guerin vaccine
Normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose (0.1 mL) contains 50 μg of the semi-dry mass of BCG bacilli, i.e. from 150,000 to 600,000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~One ampoule or vial with the powder contains: 0.5 mg (from 1.5 mln to 6 mln) of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~Powder: monosodium glutamate. Solvent: isotonic solution of sodium chloride.
Study: NCT03888924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: isotonic solution of sodium chloride (2mL vials).
Study: NCT05438641
Drug: BZDP-Based Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will received active treatment based on conventional BZDP-based protocol; additional BZDP are permitted for patients who are still symptomatic, based on CIWA-Protocol.
Study: NCT00371488
Drug: GW572016 oral tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets contain 405mg of lapatinib ditosylate monohydrate, equivalent to 250mg lapatinib free base per tablet. Oval, orange, film-coated tablets.
Study: NCT00160966
Drug: Ciclosporin and Mycophenolate-mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: according to the Giessen protocol
Study: NCT00160966
Drug: Tacrolimus and Mycophenolate-mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: according to Giessen protocol
Study: NCT04714099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01254045
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal placebo (48 international units)
Study: NCT00160966
Drug: Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: according to Giessen protocol
Study: NCT02273518
Drug: Asasantin ER, new formulation I
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02273518
Drug: Asasantin ER, new formulation II
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04393805
Drug: Low Molecular Weight Heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thromboprophylaxis with Low Molecular Weight Heparin, mostly enoxaparin
Study: NCT02273518
Drug: Asasantin ER, present commercial formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05274139
Drug: HD-MTX-Ara-C regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine~1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
Study: NCT05274139
Drug: FTD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
Study: NCT00649415
Drug: piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
Study: NCT00649415
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
Study: NCT03392961
Drug: IN-105 (Insulin Tregopil)
Normalized name: POLOXAMER 105
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg strength tablets for oral use used at a dose of 30 mg
Study: NCT01028846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral saline
Study: NCT01620489
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
Study: NCT05881109
Drug: Caspogunfin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific interventions were administrated. Participants receive interventions as part of routine medical care, where CAS was infused intravenously over 60 min at a loading dose of 70 mg/m2 on day 1, followed by a maintenance dose of 50 mg/m2 (maximum: 70 mg daily).
Study: NCT03705884
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral course of Prednisolone for treatment of sarcoidosis (patient cohort) or as control (healthy volunteer cohort)
Study: NCT01938300
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03210259
Drug: Humira®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration - 58 weeks
Study: NCT02110706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will receive a vehicle control infusion
Study: NCT04322214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily lactose capsules (as aspect cobicistat capsules)
Study: NCT04223232
Drug: [14C]-MD1003
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of 100mg \[14C\]-MD1003
Study: NCT02961218
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
Study: NCT02961218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly doses of placebo to match the administered dose of canakinumab s.c.
Study: NCT04797715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, taken twice daily
Study: NCT04256993
Drug: Other standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel, cabazitaxel, enzalutamide, abiraterone and others standard of care following the physician's prescription in routine clinical practice.
Study: NCT04094298
Drug: FX006 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of extended release triamcinolone. 32 milligram injection of the extended release triamcinolone in a 75:25 ratio of polylactic-co-glycolic acid (PLGA) microspheres to drug load of 25%. The drug product is reconstituted with diluent containing an isotonic, sterile aqueous solution of sodium chloride, carboxymethylcellulose sodium and polysorbate-80 to form a suspension prior to injection.
Study: NCT00606827
Drug: Isotonic Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to the isotonic saline group received 1 ml/kg/h 0.9% sodium chloride for 12 hours before and after the procedure
Study: NCT03534297
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard opaque capsules containing 0 mg of API.
Study: NCT02532777
Drug: Cyclophosphamide(CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00686179
Drug: AZD3480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, oral, single dose, 6 days
Study: NCT00686179
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, oral, single dose
Study: NCT02532777
Drug: Angiotensin-converting enzyme inhibitor(ACEI)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00586846
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m\^2
Study: NCT00586846
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 12g/m\^2
Study: NCT02049320
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no